Lifecare ASA

Transaction in Own Shares • Sep 25, 2024

Lifecare ASA: Re-purchase of shares and warrants completed

Lifecare ASA: Re-purchase of shares and warrants completed

Reference is made to the stock exchange announcement made by Lifecare ASA (the

"Company") earlier today, 25 September 2024, regarding the re-purchase by the

Company of up to 30,000 shares and up to 7,500 warrants in the Company in

connection with the contemplated 13:1 consolidation of the Company's shares

and warrants.

The Company has now completed the re-purchase of 30,000 shares in the Company

at an average price of NOK 1.664873 per share, and the re-purchase of 7,500

warrants in the Company at an average price of NOK 0.415 per warrant. The

purchases were carried out as ordinary trades in the market.

This information is subject to disclosure requirements pursuant to the

Norwegian Securities Trading Act section 5-12.

About us

Lifecare ASA is a clinical stage medical sensor company developing technology

for sensing and monitoring of various body analytes. Lifecare's main focus is

to bring the next generation of Continuous Glucose Monitoring ("CGM") systems

to market. Lifecare enables osmotic pressure as sensing principle, combined

with the ability to manipulate Nano-granular Tunnelling Resistive sensors

("NTR") on the sensor body for read-out of pressure variations. Lifecare's

sensor technology is referred to as "Sencell" and is suitable for identifying

and monitoring the occurrence of a wide range of analytes and molecules in the

human body and in pets.

Contacts

For further information, please contact:

Joacim Holter, CEO, joacim.holter@lifecare.no, +47 40 05 90 40

Renete Kaarvik, CFO, renete.kaarvik@lifecare.no, +47 94 83 82 42

This information is subject to disclosure under the Norwegian Securities

Trading Act, §5-12. The information was submitted for publication at

2024-09-25 12:15 CEST.